NADAC acquisition cost data for GUANFACINE HCL ER 3 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00228285311 | $0.2174 | 2022-12-21 | Rx |
| 16714019201 | $0.2174 | 2022-12-21 | Rx |
| 24979053601 | $0.2174 | 2022-12-21 | Rx |
| 60505392901 | $0.2174 | 2022-12-21 | Rx |
| 63304092601 | $0.2174 | 2022-12-21 | Rx |
| 70436004101 | $0.2174 | 2022-12-21 | Rx |
| 00228285311 | $0.2174 | 2022-12-21 | Rx |
| 16714019201 | $0.2174 | 2022-12-21 | Rx |
| 24979053601 | $0.2174 | 2022-12-21 | Rx |
| 60505392901 | $0.2174 | 2022-12-21 | Rx |
Generic: Guanfacine HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.9M | 82,275 | 17,913 | $0.5470 |
| 2020 | $3.8M | 89,987 | 17,673 | $0.6248 |
| 2021 | $4.0M | 97,173 | 19,293 | $0.6095 |
| 2022 | $4.5M | 102,390 | 20,116 | $0.6614 |
| 2023 | $4.7M | 111,820 | 22,464 | $0.6473 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.